Apollo Hospitals launched the fifth edition of its Health of the Nation 2025 (HoN-2025) report on Monday with a clear message ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the ...